Lyme disease is a bacterial illness caused primarily by infection with *Borrelia burgdorferi*, transmitted by the bite of infected *Ixodes scapularis* and *I. pacificus* ticks in the United States. Early symptoms can include a rash known as erythema migrans and influenza-like symptoms (1). Disseminated infection can cause neurologic, musculoskeletal, and cardiac complications; in rare cases, cardiac involvement can be fatal (1–4). Most patients will experience a full recovery after antibiotic treatment, although a minority may continue to experience symptoms related to disease sequelae (1).

Lyme disease case numbers consistently rank in the top 10 among all nationally notifiable conditions, and it is the most commonly reported vector-borne disease in the United States (4,5). Annually, >30,000 cases are reported to the Centers for Disease Control and Prevention (4), but recent studies have demonstrated that the annual number of diagnosed cases is ≈476,000 (6). This figure represents a substantial disease burden, but the total economic cost to US society is unknown (7).

Economic evaluations for Lyme disease have limitations (7). Most studies report direct medical costs but lack data on nonmedical costs and losses in productivity (8–11). Several studies were conducted >2 decades ago in a few Maryland counties where Lyme disease was emerging (9,11,12); however, this limited scope prevents generalizability to other areas in which the disease is endemic, and results might not be representative of today’s costs because of changes in disease management and healthcare structures. More recent studies have used diagnosis codes (e.g., International Classification of Diseases, 9th Revision, Clinical Modification) to identify Lyme disease patients from insurance claims databases. However, the low sensitivity and specificity of these codes in identifying actual cases (13,14) might lead to incorrect estimates of direct medical costs attributable to the disease. The few studies that provide more comprehensive cost estimates of Lyme disease were conducted in Europe under healthcare systems with financing structures different from those of the United States (15–17). As such, updated estimates of the total...
societal cost of Lyme disease, including direct and indirect costs, are needed in the United States (7).

We aimed to address current research gaps by conducting a prospective cost-of-illness study to estimate the economic burden of reported Lyme disease in high-incidence areas of the United States. The main objectives of this study were to estimate the patient cost and the societal cost per participant. The secondary objective was to evaluate the association of select disease and demographic factors with the societal cost per participant. Results can be used by public health officials and communities to assess the cost-effectiveness of interventions to reduce the incidence of Lyme disease.

Methods

Study Design
This study was conducted as part of TickNET, a public health network of researchers who collaborate on tickborne disease research and surveillance (18). We conducted a prospective cost-of-illness study to estimate total costs per patient caused by Lyme disease in 4 high-incidence states: Connecticut, Maryland, Minnesota, and New York. We used an incidence-based design, measuring the cost of illness from onset to conclusion (19,20). We analyzed these costs from the patient perspective (i.e., costs incurred by the patient) and the societal perspective (i.e., costs incurred by the patient, healthcare system, or third-party payer) (21,22). Cost categories included direct medical costs (clinician visits, procedures, diagnostic testing, therapy, hospitalization, emergency department visits, or other relevant costs); direct nonmedical costs (roundtrip travel costs for healthcare visits and amount paid for assistance with self-care, dependent care, or house or yard maintenance because of Lyme disease); and indirect costs, which are the cost of productivity losses (time taken off work or school because of symptoms or healthcare visits) (Appendix Table 1, https://wwwnc.cdc.gov/EID/article/28/6/21-1335-App1.pdf) (23). Henceforth, we will refer to direct medical costs as either patient medical costs (for medical costs borne by the patient) or societal medical costs (for total medical costs borne by the patient, healthcare system, and third-party payer); in addition, we will refer to direct nonmedical costs as nonmedical costs.

Study Population
The source population included pediatric and adult patients with clinician-diagnosed Lyme disease reported to public health surveillance authorities in Connecticut and Minnesota and in select counties in Maryland and New York (Appendix Table 2). Eligible patients met the national surveillance case definition for confirmed or probable disease during the study period and were referred by surveillance authorities to study personnel upon case classification (24). To ensure enrollment of incident cases only, we excluded the following cases: probable cases with no symptoms reported by the clinician, cases with a previous Lyme disease diagnosis within 2 calendar years of current diagnosis date, and cases with a diagnosis date >12 months before date of enrollment. Non-English-speaking patients were not enrolled because of limited resources for interpreters.

We classified eligible patients into 3 disease categories. Those with confirmed Lyme disease were divided into 2 groups: confirmed localized disease (i.e., those with erythema migrans) and confirmed disseminated disease (i.e., those with arthritis, lymphocytic meningitis, cranial neuritis or facial palsy, radiculoneuropathy, encephalomyelitis, or second- or third-degree heart block) (24). The third category included probable cases with symptoms reported by a clinician. To ensure enrollment of participants with a range of disease severity, we stratified recruitment by disease category and, using quota sampling, aimed to recruit approximately equal numbers of participants in each category each month. This strategy also enabled us to enroll participants as close to their diagnosis date as possible to reduce participant recall error regarding costs. Each state aimed to enroll a minimum of 50 participants per disease category; the overall minimum enrollment goal was 150 total participants per state. Recruitment and enrollment occurred during September 2014–January 2016.

Data Collection
Participants consented to data collection for either patient costs or societal costs. Study coordinators conducted introductory telephone-based surveys with participants (or legal guardians for pediatric participants) to collect data on age, sex, annual household income, insurance coverage, and disease onset date. Patient cost data were collected at the introductory survey and then approximately monthly by using the IBM SPSS Data Collection Web Interviews survey program (IBM, https://www.ibm.com). We collected the following data on all surveys: dates for Lyme disease–related healthcare visits, clinician contact information, patient medical costs, nonmedical costs, and productivity losses. Surveys ceased when participants reported no Lyme disease–related expenses.
for 2 consecutive surveys or when they completed the maximum of 12 surveys.

To calculate societal medical costs, we requested billing codes (i.e., Current Procedural Terminology [CPT], 4th Edition) directly from participants’ clinicians. We requested codes from 1 month before the self-reported disease onset date to the date of the final survey. We used a date range instead of individual visit dates reported by the participant in the event participants had incorrectly reported dates. We extracted mean reimbursement for each CPT code collected for participants with private insurance from IBM MarketScan Research Databases (IBM), which include national medical claims data for privately insured persons ≤65 years of age and their dependents, and reimbursements for CPT codes collected for nonprivately insured participants from the Physician Fee Schedule from the Centers for Medicare and Medicaid Services (25). We extracted the costs of reimbursements according to state, year, and inpatient versus outpatient status (Appendix).

Analysis
To provide an overall weighted mean and median set of reimbursements and costs, disease category sampling probabilities were estimated from disease category proportions derived from surveillance data (4) to approximate stratified random sampling. We then used the inverse of the sampling probabilities to weight the data for all analyses described. We excluded participants who did not complete 3 consecutive surveys from all analyses. We adjusted medical costs to 2016 US dollars by using the Consumer Price Index for medical care and the general Consumer Price Index for nonmedical costs and costs of productivity losses (26). We estimated the mean, median, 10th and 90th percentiles, and SDs of patient costs, societal medical costs, and total societal costs per participant. We used the Kruskal-Wallis rank-sum test to evaluate differences in cost among the 3 disease categories (confirmed localized, confirmed disseminated, probable).

To estimate the patient cost, we summed self-reported patient medical costs, nonmedical costs, and cost of productivity losses over all surveys per participant (Appendix). To calculate the societal medical costs, we summed the mean cost per CPT code collected for each participant (Appendix). Finally, we calculated the societal cost by summing the societal medical costs, patient nonmedical costs, and cost of productivity losses per participant.

We conducted multivariable linear regression analysis by using the weighted dataset to evaluate associations between the societal cost per participant and the following independent variables: disease category.

Figure 1. Flowchart of enrollment and completion by participants in study of economic burden of reported Lyme disease in high-incidence areas, United States, 2014–2016. LD, Lyme disease.
Economic Burden of Lyme Disease, United States

Table 1. Demographic characteristics of 901 participants in study of economic burden of reported Lyme disease in high-incidence areas, United States, 2014–2016

| Characteristic        | No. participants | Unweighted % | Weighted % |
|-----------------------|------------------|--------------|------------|
| Disease category*     |                  |              |            |
| Confirmed localized   | 402              | 44.6         | 54.5       |
| Confirmed disseminated| 238              | 26.4         | 21.2       |
| Probable              | 261              | 29.0         | 24.2       |
| Age group, y          |                  |              |            |
| <18                   | 259              | 28.7         | 28.4       |
| 18–45                 | 145              | 16.1         | 16.1       |
| 46–65                 | 326              | 36.2         | 36.1       |
| >65                   | 171              | 19.0         | 19.4       |
| Sex                   |                  |              |            |
| F                     | 385              | 42.7         | 43.1       |
| M                     | 516              | 57.3         | 56.9       |
| Race                  |                  |              |            |
| Non-White             | 59               | 6.5          | 6.4        |
| White                 | 842              | 93.5         | 93.6       |
| State                 |                  |              |            |
| Connecticut           | 225              | 25.0         | 23.7       |
| Maryland              | 239              | 26.5         | 26.8       |
| Minnesota             | 268              | 29.7         | 29.6       |
| New York              | 169              | 18.8         | 20.0       |
| Income†               |                  |              |            |
| <$60,000              | 238              | 29.2         | 28.8       |
| >$60,000              | 576              | 70.8         | 71.2       |
| Insurance             |                  |              |            |
| Private               | 632              | 70.1         | 70.2       |
| Other                 | 269              | 29.9         | 29.8       |
| *Disease categories were derived from the surveillance case definition for Lyme disease (24). Those with confirmed Lyme disease were divided into 2 groups: confirmed localized disease (i.e., those with erythema migrans) and confirmed disseminated disease (i.e., those with arthritis, lymphocytic meningitis, cranial neuritis or facial palsy, radiculoneuropathy, encephalomyelitis, or 2nd or 3rd degree heart block). Those classified as probable met the probable case definition, plus had ≥1 symptom reported by a clinician.†Participants were not required to provide information on income; n = 814.

Table 2. Clinician visits and duration of costs incurred, by Lyme disease category, in high-incidence areas, United States, 2014–2016

| Characteristic          | All          | Confirmed localized | Confirmed disseminated | Probable     |
|-------------------------|--------------|---------------------|------------------------|--------------|
| Median provider visits  | 2 (1–47)     | 2 (1–25)            | 3 (1–45)               | 2 (1–47)     |
| Median surveys† (range) | 3 (1–12)     | 2 (1–12)            | 3 (1–12)               | 4 (1–12)     |

*Participants began taking surveys at study enrollment and continued at approximately 1-month intervals until they reported no Lyme disease–related expenses for 2 consecutive surveys or when they completed the maximum of 12 surveys. The following were collected on all surveys: dates for Lyme disease–related healthcare visits, clinician contact information, patient medical costs, nonmedical costs, and productivity losses.

Health, and Yale University. We conducted analyses using SAS version 9.4 (SAS Institute, https://www.sas.com) and R version 3.5.2 (29–34).

Results

During the enrollment period, we identified 2,991 Lyme disease patients who were classified as having confirmed cases or probable cases with symptoms reported (Figure 1). Of the 1,360 (45%) patients we were able to contact, 1,118 (82%) consented to patient cost surveys; we included 901 (81%) participants with complete survey data in the patient cost analysis. Last, 613 (68%) of these participants also had complete societal medical cost data, and we included them in the societal cost analysis.

The study population included 402 (55%) confirmed localized, 238 (21%) confirmed disseminated, and 261 (24%) probable cases (Table 1). Overall, 36% of participants were 46–65 years of age, 57% were male, and 93.5% were white. We controlled for insurance status (private or nonprivate insurance), income (<$60,000 or ≥$60,000, which was the approximate median household income for participating states in 2015) (27), and study year (2014, 2015, 2016). As is typical for healthcare cost data, the distribution of societal cost was highly skewed, resulting in heteroskedasticity of the residuals in the model (28). Therefore, we transformed societal cost per participant by using natural logarithms and conducted sampling-weighted least squares regression (Appendix). We obtained research approval from institutional review boards at Centers for Disease Control and Prevention, Connecticut Department of Public Health, Maryland Department of Health, Minnesota Department of Health, New York State Department of Health, and Yale University. We conducted analyses using SAS version 9.4 (SAS Institute, https://www.sas.com) and R version 3.5.2 (29–34).
Table 3. Patient perspective of cost of Lyme disease per participant, by disease category, in high-incidence areas, United States, 2014–2016

| Disease category          | No. participants | Median 2016 US dollars | Mean 2016 US dollars | SD 2016 US dollars | 10th percentile 2016 US dollars | 90th percentile 2016 US dollars | Range 2016 US dollars |
|---------------------------|------------------|------------------------|----------------------|-------------------|--------------------------------|---------------------------------|------------------------|
| All†                      | 901              | 244                    | 1,252                | 2,972             | 29                             | 3,139                           | 0–30,628               |
| Confirmed localized       | 402              | 170                    | 1,070                | 4,164             | 27                             | 2,535                           | 1–26,886               |
| Confirmed disseminated    | 238              | 358                    | 1,692                | 7,323             | 32                             | 4,116                           | 2–30,628               |
| Probable                  | 261              | 315                    | 1,277                | 4,629             | 34                             | 3,987                           | 0–18,833               |

*Cost per participant according to the patient perspective represents the sum of patient medical costs, nonmedical costs, cost of productivity losses, and other related costs as reported by each participant on all surveys.
†Estimates for the overall population use the sample-weighted data except the range.

Participants reported a median of 2 provider visits and completed a median of 3 surveys (Table 2). Those with confirmed disseminated disease had the highest number of provider visits, reflecting the highest healthcare use, whereas those with probable disease had the highest number of surveys completed, reflecting the longest duration of costs incurred. Forty (4%) participants were still reporting symptoms and 25 (3%) were still incurring costs at survey 12.

Overall, the patient cost per participant ranged from $0.46 to $30,628. The median cost was $244 and the mean cost $1,252, reflecting a highly positively skewed distribution (Table 3). Participants with confirmed disseminated Lyme disease had the highest median cost ($358) and mean cost ($1,692), followed by those with probable disease (median $315 and mean $1,277), then participants with confirmed localized disease (median $170 and mean $1,070).

We calculated the median and mean cost per component of the patient cost by disease category (Figure 2; Appendix Table 4). For all disease categories, productivity losses had the highest mean cost of all cost components: $727 for those with confirmed disseminated disease, $627 for those with probable disease, and $540 for those with confirmed localized disease. However, the median cost of productivity losses for all disease categories was $0. Medical bills had the next highest cost: a median of $83 and a mean of $628 for those with confirmed disseminated disease, a median of $83 and a mean of $389 for those with probable disease, and a median of $42 and a mean of $314 for those with confirmed localized disease. All other cost components for all disease categories had median costs <$22 and mean costs <$80.

We collected 9,679 CPT codes to estimate societal medical costs. The most common codes were for office visits (17%) and routine venipuncture (6%) (Appendix Table 6). Overall, the societal medical cost per participant ranged from $50 to $121,869, for a median of $478 and mean of $1,333 (Table 4). Participants with confirmed disseminated disease had the highest median and mean societal medical cost ($696 and $2,537), followed by those with probable disease ($612 and $1,804), then confirmed localized disease ($374 and $668).

Overall, the societal cost of Lyme disease per participant ranged from $54 to $122,766; the median was $690 and the mean $2,032 (Table 5). Participants with confirmed disseminated disease had the highest median and mean societal cost ($1,081 and $3,251), followed by those with probable disease ($940 and $2,620), then confirmed localized disease ($493 and $1,307) (Appendix Table 7). Applying these per participant societal costs to estimates of the number of Lyme disease cases diagnosed each year (6), the aggregate cost to US society annually would be ≈$345 million using median costs and ≈$968 million using mean costs (2016 US dollars; Appendix Tables 9, 10).

In multivariable linear regression analysis, disease category, age, and state were associated with societal cost per participant (Table 6; Appendix Table 8). Costs for participants with confirmed disseminated disease were 120% higher than costs for participants with confirmed localized disease (p<0.001); participants with probable disease had costs that were 59% higher than those with confirmed localized disease. Participants 18–45 and 46–65 years of age had costs that were 96% and 108% higher, respectively, than those <18 years of age (p<0.001); however, those >65 years of age did not have significantly different costs. Minnesota residents had 75% higher costs than did Connecticut residents, but Maryland and New York residents did not have significantly different costs from those for Connecticut residents.

Discussion
In this study, persons with confirmed or probable Lyme disease had an average patient cost of $1,200 (median cost ≈$240) and an average societal cost of $2,000 (median cost ≈$700). In stratified analyses by disease category, those with confirmed disseminated
or probable disease had double or more the societal cost per participant than those with confirmed localized disease, highlighting the importance of early and accurate diagnosis. Having disseminated or probable disease, being 18–65 years of age, and residing in Minnesota had the greatest effects on the societal cost of Lyme disease. Although median societal costs were typically ≤$1,000 for all disease categories, mean costs were substantially higher, indicating that most patients have low costs, but some experience very high costs related to this disease. Similarly, the low median number of provider visits and hours of lost productivity suggest that Lyme disease illness is manageable for most patients, but for a minority, it can be highly disruptive. Approximately 476,000 cases of Lyme disease are diagnosed each year in the United States, so the aggregate cost to society annually could be $345–968 million (2016 US dollars). This substantial economic burden underscores the need for effective prevention methods, such as a vaccine.

Classification of a reported case as probable means a clinician has diagnosed Lyme disease in a patient and laboratory evidence of infection exists. However, any reported symptoms are typically

![Figure 2](https://www.cdc.gov/eid/content/images/leaves.png)

**Figure 2.** Mean and median cost per participant, by Lyme disease category and cost category of the total patient cost in high-incidence areas of the United States, 2014–2016. A) Confirmed localized disease; B) confirmed disseminated disease; C) probable disease. Black lines indicate median cost.
Table 4. Societal perspective of medical cost of Lyme disease per participant, by disease category, in high-incidence areas, United States, 2014–2016

| Disease category          | No. participants | Median | Mean  | SD    | 10th percentile | 90th percentile | Range            |
|---------------------------|------------------|--------|-------|-------|-----------------|-----------------|------------------|
| All†                      | 613              | 478    | 1,333 | 5,690 | 164             | 1,932           | 50–121,869       |
| Confirmed localized       | 273              | 374    | 668   | 1,715 | 136             | 2,224           | 50–13,050        |
| Confirmed disseminated    | 154              | 696    | 2,537 | 20,220| 259             | 4,366           | 147–121,869      |
| Probable                  | 186              | 612    | 1,804 | 15,188| 237             | 4,545           | 124–105,494      |

*Societal medical cost per participant excludes Current Procedural Terminology (CPT) codes deemed unrelated to Lyme disease as determined by a physician subject matter expert (Appendix Table 5, https://wwwnc.cdc.gov/EID/article/28/6/1335-App1.pdf).
†Estimates for the overall population use the sample-weighted data except the range.

In a geographically limited study of Lyme disease patients residing on the eastern shore of Maryland during 1998–2001, Zhang et al. (9) reported mean total costs of $3,494 and median total costs of $500 (2016 US dollars) per patient attributable to this disease. However, their case definition differed from ours in its inclusion of patients with early, late, and suspected disease, as well as those with tick bite and other related complaints, as identified using diagnosis codes in medical records. Therefore, these figures might not be directly comparable to our mean and median societal costs ($2,032 and $690). Zhang et al. reported mean and median total costs of $2,275 and $689 (2016 US dollars) for participants with clinically defined early disease, which are higher than what we found for confirmed localized disease (mean $1,307 and median $493). However, in regression analyses, Zhang et al. found that disease category and age, but not sex, were significantly associated with societal medical costs, similar to our findings for societal cost. In another US study using nationwide commercial insurance claims data to compare cases with matched controls during 2006–2010, Adrion et al. (8) estimated an increase of $3,009 (2016 US dollars) in societal medical costs attributable to Lyme disease over a 12-month period. That cost is higher than our overall mean societal medical cost ($1,333), likely because of study population differences, but is similar to that found for our participants with confirmed disseminated disease ($2,537). In a recent study in the Netherlands, Van den Wijngaard et al. (17) used a societal perspective to estimate a total cost of $137 for patients with erythema migrans only and $6,398 (2016 US dollars) for those with disseminated Lyme borreliosis. These costs are lower than those for our societal results for confirmed localized disease ($1,307) and higher than those for our societal results for confirmed disseminated disease ($3,251). These cost differences might result from different healthcare financing systems in the United States versus Europe or from variations in clinical manifestations resulting from infection with different B. burgdorferi sensu lato strains (15–17).

Our study adds to the scarce literature on the economic burden of Lyme disease and provides a comprehensive estimate of its costs to both the patient and society. In addition, our prospective collection of all patient costs, including nonspecific costs and productivity losses, enables more accurate and more comprehensive cost estimates compared with previous studies in the United States. Further, these results provide estimates of the cost savings per case averted, which can be used in cost-benefit analyses of prevention interventions, such as a potential vaccine.

The first limitation of our study is that our estimates might be affected by recall error, either by...

Table 5. Societal perspective of total cost of Lyme disease per participant, by disease category, in high-incidence areas, United States, 2014–2016

| Disease category          | No. participants | Median | Mean  | SD    | 10th percentile | 90th percentile | Range            |
|---------------------------|------------------|--------|-------|-------|-----------------|-----------------|------------------|
| All†                      | 613              | 690    | 2,032 | 6,091 | 203             | 4,201           | 54–122,766       |
| Confirmed localized       | 273              | 493    | 1,307 | 3,559 | 154             | 2,678           | 54–18,322        |
| Confirmed disseminated    | 154              | 1,081  | 3,251 | 20,908| 297             | 6,238           | 216–122,766      |
| Probable                  | 186              | 940    | 2,620 | 15,533| 316             | 5,021           | 130–105,500      |

*Total cost per participant according to the societal perspective includes medical costs, patient nonmedical costs, and cost of productivity losses. Patient medical costs were not added because they are already included in societal medical costs.
†Estimates for the overall population use the sample-weighted data except the range.
participants or providers, although we attempted to mitigate such error by enrolling patients as close to disease onset as possible, by surveying them monthly to capture ongoing costs, and by requesting codes from providers for a date range instead of for individual visits. However, by requesting codes over a date range, some billing codes unrelated to Lyme disease (e.g., for other comorbidities) might have been included despite our excluding codes definitively unrelated to Lyme disease, potentially leading to overestimates. Information bias might have occurred in our measure of association between disease category and cost because those with milder disease might be more likely to forget some costs than those with more severe disease, with a potential bias away from null. In addition, although the use of quota sampling to recruit reported cases was necessary to enroll patients near disease onset, this nonprobability sampling method limits our ability to meet assumptions for calculating sampling error. Use of surveillance data to weight responses by disease category was intended to ensure representativeness by disease category. Nevertheless, in surveillance data, confirmed localized cases are likely underreported, resulting in confirmed disseminated cases representing an artificially large proportion of cases; therefore, our overall cost might be overestimated (35,36). Finally, this study did not include costs related to deaths from Lyme disease, because no enrolled participants died. Although very rare, death from Lyme carditis has been reported (2,3), and associated productivity losses would greatly increase cost estimates.

Our results reflect the costs of diagnosed cases meeting the Lyme disease surveillance case definition in high-incidence states (24); as such, these costs likely reflect that of actual infections. However, we were not able to evaluate whether our estimates accurately represent the cost of diagnosed but unreported Lyme disease, cases that reflect some proportion of overdiagnosis (6). Further, our results might not reflect costs in states with emerging or low incidence of Lyme disease. Therefore, our results for extrapolation of costs to an estimated \( \approx \)476,000 diagnosed cases nationally per year should be interpreted with caution. Last, our results do not include costs for suspected Lyme disease (e.g., consultation and prophylactic treatment for tick bite, negative diagnostic tests), undiagnosed disease, or nonacute disease (e.g., patients experiencing long-term symptoms). These costs would further increase the total economic burden attributable to Lyme disease. Future efforts should include cost-effectiveness analyses of current and future prevention methods, such as a vaccine, in addition to economic evaluations of unreported, suspected, and nonacute disease.

In conclusion, Lyme disease represents a substantial economic burden to individual patients and US society. The aggregate cost of diagnosed Lyme disease could be nearly $1 billion annually, not including suspected, undiagnosed, or nonacute cases. These findings emphasize the importance of early and accurate diagnosis to reduce both illness and its associated personal and societal costs.

---

**Table 6.** Impact of disease category, age group, sex, and state on total societal cost of Lyme disease per participant, United States, 2014–2016 (n = 613)*

| Variable                      | % Difference | Total cost difference, 2016 US dollars (95% CI) |
|-------------------------------|--------------|-----------------------------------------------|
| Baseline cost†                | NA           | 305 (206–451)                                 |
| Lyme disease category         |              |                                               |
| Confirmed, localized          | Referent     | Referent                                      |
| Confirmed, disseminated       | 120          | 367 (188–545)                                |
| Probable                      | 59           | 181 (71–291)                                 |
| Age group, y                  |              |                                               |
| <18                           | Referent     | Referent                                      |
| 18–45                         | 96           | 293 (107–479)                                |
| 46–65                         | 108          | 331 (175–486)                                |
| >65                           | 27           | 84 (–26 to 195)                              |
| Sex                           |              |                                               |
| F                             | Referent     | Referent                                      |
| M                             | 11           | 35 (–26 to 95)                               |
| State                         |              |                                               |
| Connecticut                   | Referent     | Referent                                      |
| Maryland                      | 0            | 0 (–76 to 76)                                |
| Minnesota                     | 75           | 229 (114–345)                                |
| New York                      | –6           | –19 (–119 to 82)                             |

*Results from sample-weighted multivariable linear regression analysis. The model includes independent variables of interest (i.e., disease category, age group, sex, and state), while controlling for insurance status, income, and study year (Appendix, https://wwwnc.cdc.gov/EID/article/28/6/21-1335-App1.pdf). Adjusted \( R^2 = 0.19 \).

†Baseline cost represents a patient with confirmed localized Lyme disease, female, <18 years of age, residing in Connecticut, without private insurance, with income <$60,000, in the study year of 2014.
Acknowledgments
We thank Nadia Thomas, Shaylee Mehta, David Neitzel, Elizabeth Schiffman, Molly Peterson, Julie Ray, Jamie Sommer, Robert Heimer, Mark Lamias, Craig Mincic, and John Jones for their assistance in conducting this study; Brad Biggerstaff, Zach Weller, and Josh Keller for their statistical advice; and Paul Mead, Jennifer Peel, Jude Bayham, Sheryl Magzamen, and Brooke Anderson for their valuable insights during manuscript preparation.

This work was supported by the Centers for Disease Control and Prevention.

About the Author
Dr. Hook is an epidemiologist in the Bacterial Diseases Branch, Division of Vector-Borne Diseases, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado. Her primary research interests are the epidemiology and prevention of bacterial vector-borne infections.

References
1. Wormser GP, Dattwyler RJ, Shapiro ED, Halperin JJ, Steere AC, Klempern MS, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2006;43:1089–134. https://doi.org/10.1086/508677
2. Forrester JD, Mead P. Third-degree heart block associated with Lyme carditis: review of published cases. Clin Infect Dis. 2014;59:996–1000. https://doi.org/10.1093/cid/ciu411
3. Forrester JD, Meiman J, Mullins J, Nelson R, Ertel SH, Carter M, et al.; Centers for Disease Control and Prevention (CDC). Notes from the field: update on Lyme carditis, groups at high risk, and frequency of associated sudden cardiac death—United States. MMWR Morb Mortal Wkly Rep. 2014;63:982–3.
4. Schwartz AM, Hinckley AF, Mead PS, Hook SA, Kugeler KJ. Surveillance for Lyme disease—United States, 2008–2015. MMWR Surveill Summ. 2017;66:1–12. https://doi.org/10.15585/mmwr.su6602a1
5. Rosenberg R, Lindsey NP, Fischer M, Gregory CJ, Hinckley AF, Mead PS, et al. Vital signs: trends in reported vectorborne disease cases—United States and territories, 2004–2016. MMWR Morb Mortal Wkly Rep. 2018;67:496–501. https://doi.org/10.15585/mmwr.mm6718e1
6. Kugeler KJ, Schwartz AM, Delorey MJ, Mead PS, Hinckley AF. Estimating the frequency of Lyme disease diagnoses, United States, 2010–2018. Emerg Infect Dis. 2021;27:616–9. https://doi.org/10.3201/eid2702.202731
7. Mac S, da Silva SR, Sander B. The economic burden of Lyme disease and the cost-effectiveness of Lyme disease interventions: a scoping review. PLoS One. 2019;14:e0210280. https://doi.org/10.1371/journal.pone.0210280
8. Aderin ER, Aucott J, Lemke KW, Weiner JP. Health care costs, utilization and patterns of care following Lyme disease. PLoS One. 2015;10:e0116767. https://doi.org/10.1371/journal.pone.0116767
9. Zhang X, Meltzer MI, Peña CA, Hopkins AB, Wroth L, Fix AD. Economic impact of Lyme disease. Emerg Infect Dis. 2006;12:653–60. https://doi.org/10.3201/eid1204.050602
10. Strickland GT, Karp AC, Mathews A, Peña CA. Utilization and cost of serologic tests for Lyme disease in Maryland. J Infect Dis. 1997;176:819–21. https://doi.org/10.1086/517311
11. Fix AD, Strickland GT, Grant J. Tick bites and Lyme disease in an endemic setting: problematic use of serologic testing and prophylactic antibiotic therapy. JAMA. 1998;279:206–10. https://doi.org/10.1001/jama.279.3.206
12. Strickland GT, Caisley J, Woubeshet M, Israel E. Antibiotic therapy for Lyme disease in Maryland. Public Health Rep. 1994;109:745–9.
13. Rutz H, Hogan B, Hook S, Hinckley A, Feldman K. Exploring an alternative approach to Lyme disease surveillance in Maryland. Zoonoses Public Health. 2018;65:254–9. https://doi.org/10.1111/zph.12446
14. White J, Noonan-Toly C, Lukacik G, Thomas N, Hinckley A, Hook S, et al. Lyme disease surveillance in New York state: an assessment of case underreporting. Zoonoses Public Health. 2018;65:238–46. https://doi.org/10.1111/zph.12307
15. Lohr B, Müller I, Mai M, Norris DE, Schöffski O, Hunfeld KP. Epidemiology and cost of hospital care for Lyme borreliosis in Germany: lessons from a health care utilization database analysis.Ticks Tick Borne Dis. 2015;6:56–62. https://doi.org/10.1016/j.jtbdis.2014.09.004
16. Joss AW, Davidson MM, Ho-Yen DO, Ludbrook A. Lyme disease—what is the cost for Scotland? Public Health. 2003;117:264–7. https://doi.org/10.1016/S0033-3506(03)00672-7
17. van den Wijngaard CC, Hofhuis A, Wong A, Harms MG, de Wit GA, Lugner AK, et al. The cost of Lyme borreliosis. Eur J Public Health. 2017;27:538–47. https://doi.org/10.1093/eurpub/ckw269
18. Mead P, Hinckley A, Hook S, Beard CB. TickNET—a collaborative public health approach to tickborne disease surveillance and research. Emerg Infect Dis. 2015;21:1574–7. https://doi.org/10.3201/eid2109.150301
19. Jo C. Cost-of-illness studies: concepts, scopes, and methods. Clin Mol Hepatol. 2014;20:327–37. https://doi.org/10.3350/cmh.2014.20.4.327
20. Tarricone R. Cost-of-illness analysis. What room in health economics? Health Policy. 2006;77:51–63. https://doi.org/10.1016/j.healthpol.2005.07.016
21. Rice DP. Cost of illness studies: what is good about them? Inj Prev. 2000;6:177–9. https://doi.org/10.1136/ip.6.3.177
22. Rice DP. Estimating the cost of illness. Am J Public Health Nations Health. 1967;57:424–40. https://doi.org/10.2105/ajph.57.3.424
23. Meltzer MI. Introduction to health economics for physicians. Lancet. 2001;358:993–8. https://doi.org/10.1016/S0140-6736(01)06107-4
24. Centers for Disease Control and Prevention. Lyme disease (Borrelia burgdorferi) 2008 case definition. 2008 [cited 2019 Oct 18]. https://www.cdc.gov/ndss/conditions/lyme-disease/case-definition/2008
25. Centers for Medicare and Medicaid. PFS national payment amount file. 2019 [cited 2019 Nov 6]. https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeeSched/PFS-National-Payment-Amount-File.html
26. US Bureau of Labor Statistics. Historical consumer price index for all urban consumers (CPI-U) [cited 2019 Jun 27]. https://www.bls.gov/cpi/tables/supplemental-files/index for all urban consumers (CPI-U) [cited 2019 Jun 27]. https://www.census.gov/content/dam/Census/library/publications/2016/acs/acsbr15-02.pdf
27. Posey KG. Household Income: 2015. 2016 [cited 2022 Feb 1]. https://www.census.gov/content/dam/Census/library/publications/2016/acs/acsbr15-02.pdf
28. Mihaylova B, Briggs A, O’Hagan A, Thompson SG. Review of statistical methods for analysing healthcare resources and
costs. Health Econ. 2011;20:897–916. https://doi.org/10.1002/hec.1653
29. Wickham H. tidyverse: easily install and load the ‘Tidyverse.’ R package version 1.2.1 ed; 2017 [cited 2022 May 3]. https://cran.r-project.org/web/packages/tidyverse/index.html
30. Freedman GE. srvyr: ‘dplyr’-like syntax for summary statistics of survey data. R package version 0.3.4 ed; 2019 [cited 2022 May 3]. https://cran.r-project.org/web/packages/srvyr/index.html
31. Lumley T. Survey: analysis of complex survey samples R package version 3.35–1 ed; 2019 [cited 2022 May 3]. https://cran.r-project.org/web/packages/survey/index.html
32. Long J. jtools: Analysis and presentation of social scientific data. R package version 2.0.1 ed; 2019 [cited 2022 May 3]. https://cran.r-project.org/web/packages/jtools/index.html
33. Wei T, Simko V. R package “corrplot”: visualization of a correlation matrix (version 0.84). Version 0.84 ed; 2017 [cited 2022 May 3]. https://wwwnc.cdc.gov/eid/article/26/12/2612_article

etymologia revisited
Salmonella
[sal’′′mo-nel’′a]

Named in honor of Daniel Elmer Salmon, an American veterinary pathologist, Salmonella is a genus of motile, gram-negative bacillus, nonspore-forming, aerobic to facultatively anaerobic bacteria of the family Enterobacteriaceae. In 1880, Karl Joseph Eberth was the first to observe Salmonella from specimens of patients with typhoid fever (from the Greek typhōdes [like smoke; delirious]), which was formerly called Eberthella typhosa in his tribute. In 1884, Georg Gaffky successfully isolated this bacillus (later described as Salmonella Typhi) from patients with typhoid fever, confirming Eberth’s findings. Shortly afterward, Salmon and his assistant Theobald Smith, an American bacteriologist, isolated Salmonella Choleræusis from swine, incorrectly assuming that this germ was the causative agent of hog cholera. Later, Joseph Lignières, a French bacteriologist, proposed the genus name Salmonella in recognition of Salmon’s efforts.

Sources:
1. Dorland’s Illustrated Medical Dictionary. 32nd ed. Philadelphia: Elsevier Saunders; 2012.
2. Gossner CM, Le Hello S, de Jong B, Rolffhame P, Fænsen D, Weill FX, et al. Around the world in 1,475 Salmonella ge-serotypes [Another Dimension]. Emerg Infect Dis. 2016;22:1298–302.
3. Issenhuth-Jeanjean S, Roggentin P, Mikoleit M, Guibourdenche M, de Pinna E, Nair S, et al. Supplement 2008-2010 (no. 48) to the White-Kaufmann-Le Minor scheme. Res Microbiol. 2014;165:526–30.
4. Salmon DE. The discovery of the germ of swine-plague. Science. 1884;3:155–8.
5. Su LH, Chiu CH. Salmonella: clinical importance and evolution of nomenclature. Chang Gung Med J. 2007;30:210–9.
Economic Burden of Reported Lyme Disease in High-Incidence Areas, United States, 2014–2016

Appendix

Section 1. Detailed Description of Cost Calculations for Total Patient Cost (Patient Perspective) and Societal Medical Costs (Societal Perspective)

To estimate the total patient cost, we summed self-reported medical costs, nonmedical costs, cost of productivity losses, and other related costs over all surveys. For nonmedical costs related to travel for clinician, pharmacy, or laboratory visits, the self-reported roundtrip mileage per visit was multiplied by the standard mileage rate from the Internal Revenue Service for the respective year (1). To calculate cost estimates for productivity losses, self-reported hours missed from work for adult participants or parents of pediatric participants were multiplied by the hourly earnings by age and sex derived from Grosse et al. (2), which uses the human capital approach to estimate annual market and non-market productivity from the US Census Bureau’s American Community Survey and American Time Use Survey.

We calculated the societal medical cost per participant (regardless of who pays) by summing the mean cost per CPT code collected for each participant. The codes represented clinician visits, consultation and related in-office procedures, diagnostic testing, therapy, hospitalization, emergency department (ED) visits, or other procedures or relevant costs. Mean cost for each CPT code collected for participants with private insurance was extracted from IBM MarketScan Research Databases, which include national medical claims data for privately insured persons up to age 65 and their dependents. Costs for CPT codes collected for non-privately insured participants were extracted from the Physician Fee Schedule National Payment Amount File from the Centers for Medicare and Medicaid Services (CMS) (3). Both MarketScan and CMS costs reflect reimbursements made for charges for medical procedures and services and include the amount paid by the insurer as well as the beneficiary (such as deductibles, copays,
and coinsurance). We did not collect billing codes from pharmacies or laboratories. Therefore, we extracted the mean cost of the recommended antibiotics for Lyme disease (LD) by state and study year from MarketScan drug cost data and added this cost to each participant’s total societal medical cost (4–8). Because laboratory evidence of infection is required to meet criteria for confirmed disseminated or probable disease (9), we added the cost of the recommended two-tiered LD diagnostic testing to the total societal medical cost for all participants in these disease categories who did not already have these CPT codes documented. We excluded from analysis participants for whom CPT code collection was incomplete due to provider nonresponse to code collection requests. We also excluded individual CPT codes deemed unrelated to LD, per consultation with an infectious disease physician, that were collected coincidentally from providers (Appendix Table 5).

Equation 1. Multivariable Linear Regression Model Equation

We used a multivariable linear regression model to estimate the relative impact of our independent variables of interest on the total societal cost of LD per participant. As is typical for healthcare cost data, the distribution of total cost was highly skewed, resulting in heteroskedasticity of the residuals in the model (10). Therefore, we transformed total societal cost per participant using natural logarithms and conducted sampling-weighted least squares regression. The basic equation is as follows:

$$\log(y_i) = \beta_0 + \beta_x x_i + \epsilon_i$$

where $Y_i$ is the dependent variable, the total societal cost of LD for patient $i$; $X_i$ is a vector of covariates; and $\epsilon_i$ is a mean-zero random error. The equation is written as follows for our specific vector of covariates (i.e., independent variables of interest and potential confounders):

$$\log(y_i) = \beta_0 + \beta_1 \text{Disease category} + \beta_2 \text{Age group} + \beta_3 \text{Sex} + \beta_4 \text{State} + \beta_5 \text{Insurance status} + \beta_6 \text{Income} + \beta_7 \text{Study year} + \epsilon_i$$

Baseline costs came from the intercept term, $\beta_0$, which represents a patient with confirmed localized Lyme disease, female, aged <18 years, with residence in CT, without private insurance, with income <$60,000, and study year of 2014. Resulting $\beta$ coefficients were back
transformed by exponentiation, interpreted as the multiplicative difference in the geometric mean of the total cost of Lyme disease for a 1-unit difference in the independent variable of interest after adjusting for confounders. For interpretability, we calculated the percent difference in cost from baseline for each level of each independent variable, excluding reference (i.e., baseline) levels (Percent difference = (Exp(coefficient) – 1) * 100). These additional costs were added or subtracted to the baseline costs for each independent variable of interest (Table 6, LINK; Appendix Table 8).

Section 2. Description of Calculations for Extrapolation of Total Societal LD Cost Per Participant to Annual, Aggregate Total LD Cost to U.S. Society

Previous research has demonstrated that LD surveillance case numbers are likely 8–12-fold underreported (11,12), with a recent study estimating 476,000 diagnosed cases per year (13).

The table below shows total cases by confirmed localized, confirmed disseminated, and probable disease per the proportions found in surveillance data. Case numbers by disease category are multiplied by the mean and median total cost per participant estimated from this study to get the aggregate cost per disease category (Appendix Table 9). When summed, the mean total cost of LD in the U.S. annually is approximately $968,444,834, while the median is $345,164,936 (2016 USD, Appendix Table 10). In 2020 USD, the mean cost is $1,039,260,297 using the Consumer Price Index (CPI) for all consumers and $1,078,657,584 when using the CPI for medical care (14), with median costs at $370,404,385 and $384,446,034, respectively (Appendix Table 10).

References

1. Standard Mileage Rates IRS. 2019 [cited 2019 7/22/2019]; Available from: https://www.irs.gov/tax-professionals/standard-mileage-rates

2. Grosse SD, Krueger KV, Pike J. Estimated annual and lifetime labor productivity in the United States, 2016: implications for economic evaluations. J Med Econ. 2019;22:501–8. PubMed
   https://doi.org/10.1080/13696998.2018.1542520

3. Centers for Medicare and Medicaid. PFS National Payment Amount File. 2019 [cited 2019 Nov 6]. https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeeSched/PFS-National-Payment-Amount-File.html
4. Hu LT. Lyme Disease. Ann Intern Med. 2016;165:677. PubMed https://doi.org/10.7326/L16-0409

5. Kowalski TJ, Tata S, Berth W, Mathiason MA, Agger WA. Antibiotic treatment duration and long-term outcomes of patients with early Lyme disease from a Lyme disease-hyperendemic area. Clin Infect Dis. 2010;50:512–20. PubMed https://doi.org/10.1086/649920

6. Sanchez E, Vannier E, Wormser GP, Hu LT. Diagnosis, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: A Review. JAMA. 2016;315:1767–77. PubMed https://doi.org/10.1001/jama.2016.2884

7. Stupica D, Lusa L, Ruzić-Sabljić E, Cerar T, Strlé F. Treatment of erythema migrans with doxycycline for 10 days versus 15 days. Clin Infect Dis. 2012;55:343–50. PubMed https://doi.org/10.1093/cid/cis402

8. Centers for Disease Control and Prevention. Lyme disease treatment. 2020 [cited 2020 Feb 13]. https://www.cdc.gov/lyme/treatment/index.html

9. Centers for Disease Control and Prevention. Lyme Disease (Borrelia burgdorferi) 2008 Case Definition. 2008 [cited 2019 Oct 18]. https://wwwn.cdc.gov/nndss/conditions/lyme-disease/case-definition/2008/

10. Mihaylova B, Briggs A, O’Hagan A, Thompson SG. Review of statistical methods for analysing healthcare resources and costs. Health Econ. 2011;20:897–916. PubMed https://doi.org/10.1002/hec.1653

11. Nelson CA, Saha S, Kugeler KJ, Delorey MJ, Shankar MB, Hinckley AF, et al. Incidence of clinician-diagnosed Lyme disease, United States, 2005–2010. Emerg Infect Dis. 2015;21:1625–31. PubMed https://doi.org/10.3201/eid2109.150417

12. Hinckley AF, Connally NP, Meek JI, Johnson BJ, Kemperman MM, Feldman KA, et al. Lyme disease testing by large commercial laboratories in the United States. Clin Infect Dis. 2014;59:676–81. PubMed https://doi.org/10.1093/cid/ciu397

13. Kugeler KJ, Schwartz AM, Delorey MJ, Mead PS, Hinckley AF. Estimating the frequency of Lyme Disease diagnoses, United States, 2010–2018. Emerg Infect Dis. 2021;27:616–9. PubMed https://doi.org/10.3201/eid2702.202731

14. U.S. Bureau of Labor Statistics. Databases, Tables & Calculators by Subject. 2020 [cited 2020 Sep 30]. https://data.bls.gov/pdq/SurveyOutputServlet

15. Meltzer MI. Introduction to health economics for physicians. Lancet. 2001;358:993–8. PubMed https://doi.org/10.1016/S0140-6736(01)06107-4
**Appendix Table 1.** Cost categories and inclusion of costs dependent on perspective for economic analysis*

| Cost categories                | Examples of costs                        | Patient Perspective | Society Perspective |
|--------------------------------|------------------------------------------|---------------------|---------------------|
| Direct medical                 |                                          |                     |                     |
| Direct medical                 | Healthcare personnel time                | Included            | Included            |
|                                | Drugs or other therapy                   | Included            | Included            |
|                                | Laboratory tests                         | Included            | Included            |
|                                | Medical devices, supplies, equipment     | Not included        | Included            |
| Direct nonmedical              | Administrative resources                 | Not included        | Included            |
|                                | Healthcare facility                      | Not included        | Included            |
|                                | Utilities                                | Not included        | Included            |
|                                | Patient’s travel cost                    | Included            | Included            |
|                                | Hired caregiving                         | Included            | Included            |
|                                | Hired household help                     | Included            | Included            |
| Indirect                       | Time off work for healthcare visits      | Included            | Included            |
|                                | Time off work due to symptoms            | Included            | Included            |

*Source: adapted from Meltzer MI (15).
†Economic analyses are usually conducted from the following perspectives: patient, clinician, hospital, third-party payer, and/or society.
‡The societal perspective includes all costs related to an illness, no matter who pays, and is typically the sum of costs paid by the patient, clinician, hospital, and third-party payer.

**Appendix Table 2.** Participating counties from Maryland and New York

| State | County         |
|-------|----------------|
| Maryland | Anne Arundel  |
|        | Baltimore      |
|        | Calvert        |
|        | Carroll        |
|        | Cecil          |
|        | Frederick      |
|        | Harford        |
|        | Howard         |
|        | Montgomery     |
| New York | Albany        |
|        | Rensselaer     |
|        | Columbia       |
|        | Greene         |
|        | Saratoga       |
|        | Schoharie      |
|        | Schenectady    |
|        | Washington     |
|        | Fulton         |
|        | Montgomery     |
|        | Ostego         |
|        | Delaware       |
|        | Dutchess       |
|        | Ulster         |
Appendix Table 3. Characteristics of the subset of participants with complete patient cost and societal medical cost data, n = 613

| Characteristic | Category | No.   | Unweighted % | Weighted % |
|---------------|----------|-------|--------------|------------|
| Disease category | Confirmed localized | 273 | 44.5 | 54.4 |
|                | Confirmed disseminated | 154 | 25.1 | 20.2 |
|                | Probable | 186 | 30.3 | 25.4 |
| Age group, y  | <18 | 173 | 28.2 | 27.7 |
|               | 18-45 | 96 | 15.7 | 15.7 |
|               | 46-65 | 228 | 37.2 | 37.0 |
| Sex           | Female | 262 | 42.7 | 43.0 |
|               | Male  | 351 | 57.3 | 57.0 |
| Race          | Non-White | 45 | 7.3 | 7.1 |
|               | White | 568 | 92.7 | 92.9 |
| State         | CT | 128 | 20.9 | 19.3 |
|               | MD | 203 | 33.1 | 33.6 |
|               | MN | 191 | 31.2 | 31.1 |
|               | NY | 91 | 14.8 | 15.9 |
| Income*        | ≤$60,000 | 160 | 28.7 | 28.4 |
|               | >$60,000 | 398 | 71.3 | 71.6 |
| Insurance      | Private | 438 | 28.5 | 28.5 |
|               | Other | 175 | 71.5 | 71.5 |
| Median clinician visits (range) | 2 (1–33) | NA | NA |
| Median surveys (range) | 3 (1–12) | NA | NA |

*Participants were not required to provide information on income; n = 558.

Appendix Table 4. Mean and median patient Lyme disease costs per participant, by disease and cost category, 2016 US dollars*

| Cost category         | Confirmed localized disease | Confirmed disseminated disease | Probable disease |
|-----------------------|----------------------------|-------------------------------|-----------------|
|                       | Median (95% CI) | Mean (95% CI) | Median (95% CI) | Mean (95% CI) | Median (95% CI) | Mean (95% CI) |
| Productivity losses   | 0 (0–0) | 540 (368–712) | 0 (0–0) | 727 (359–1095) | 0 (0–0) | 627 (429–824) |
| Medical bills          | 42 (31–52) | 314 (201–426) | 83 (61–145) | 628 (405–849) | 83 (62–99) | 389 (264–514) |
| Prescription medicine  | 16 (11–21) | 56 (32–80) | 21 (17–21) | 79 (64–105) | 19 (16–21) | 44 (34–54) |
| Over-the-counter medicine | 0 (0–4) | 20 (13–27) | 10 (7–10) | 53 (28–78) | 5 (2–8) | 47 (21–72) |
| Transportation         | 11 (10–12) | 34 (16–52) | 20 (17–23) | 55 (37–74) | 18 (14–20) | 49 (30–69) |
| Home maintenance       | 0 (0–0) | 31 (7–55) | 0 (0–0) | 58 (12–103) | 0 (0–0) | 50 (4–97) |
| Other                  | 0 (0–0) | 40 (23–58) | 0 (0–0) | 78 (37–118) | 0 (0–0) | 51 (27–75) |
| Care for self/dependents | 0 (0–0) | 35 (9–91) | 0 (0–0) | 14 (0–28) | 0 (0–0) | 20 (4–42) |

Appendix Table 5. List of CPT codes removed from analyses, code description, frequency, mean cost per code (n = 30)*

| CPT code | Code description                          | N | Mean cost (2016 USD) |
|----------|------------------------------------------|---|---------------------|
| 11406    | Removal of growth (4.0 cm) of the trunk, arms, or legs | 1 | 1152 |
| 11606    | Removal of malignant growth (over 4.0 cm) of the trunk, arms, or legs | 1 | 1240 |
| 36475    | Destruction of insufficient vein of arm or leg, accessed through the skin | 1 | 3021 |
| 37609    | Tying or biopsy of temporal artery (side of skull) | 1 | 1844 |
| 42821    | Removal of tonsils and adenoid glands patient age 12 or over | 1 | 1946 |
| 42830    | Removal of adenoids patient younger than age 12 | 1 | 1854 |
| 43238    | Ultrasound guided needle aspiration or biopsies of esophagus using an endoscope | 1 | 2864 |
| 45378    | Diagnostic examination of large bowel using an endoscope | 4 | 752 |
| 45380    | Biopsy of large bowel using an endoscope | 1 | 1131 |
| 45385    | Removal of polyps or growths of large bowel using an endoscope | 2 | 2911 |
| 47562    | Removal of gallbladder using an endoscope | 1 | 4062 |
| 55700    | Biopsy of prostate gland | 1 | 679 |
| 59510    | Cesarean delivery with pre- and post-delivery care | 1 | 2893 |
| 62311    | Injections of substances into lower or sacral spine | 3 | 565 |
| 64490    | Injections of upper or middle spine facet joint using imaging guidance | 1 | 788 |
| 64491    | Injections of upper or middle spine facet joint using imaging guidance | 1 | 531 |
| 64492    | Injections of upper or middle spine facet joint using imaging guidance | 1 | 502 |
| 64635    | Destruction of lower or sacral spinal facet joint nerves using imaging guidance | 1 | 1155 |
| 64636    | Destruction of lower or sacral spinal facet joint nerves with imaging guidance | 1 | 801 |
| 66984    | Removal of cataract with insertion of lens | 3 | 2415 |
| 69436    | Incision of eardrum with insertion of eardrum tube under general anesthesia | 1 | 1802 |
| 79562    | Lung ventilation and perfusion imaging | 1 | 598 |
| 92928    | Catheter insertion of stents in major coronary artery or branch, accessed through the skin | 1 | 3530 |
| CPT code | Code description | N | Mean cost (2016 USD) |
|----------|------------------|---|---------------------|
| 95810    | Sleep monitoring of patient (6 y or older) in sleep lab | 1 | 1535 |
| C1725    | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 2 | 2182 |
| C1874    | Stent, coated/covered, with delivery system | 1 | 5411 |
| C9600    | Percutaneous transcatheter placement of drug eluting intracoronary stent(s), with coronary angioplasty when performed; single major coronary artery or branch | 1 | 12616 |
| G0202    | Screening mammography digital | 14 | 490 |
| G0206    | Diagnostic mammography digital | 3 | 523 |
| J0133    | Injection, acyclovir, 5 mg | 1 | 824 |

*An infectious disease physician with subject matter expertise in Lyme disease deemed these CPT codes to be unrelated to Lyme disease; 54 instances with these 30 codes recorded were deleted from the dataset before all analyses.

Appendix Table 6. Twenty-five most frequently reported CPT codes, code description, and summary statistics

| CPT code | Code description | N | Proportion | MarketScan mean, median reimbursement (USD 2016) | CMS mean, median reimbursement (USD 2016) |
|----------|------------------|---|------------|-----------------------------------------------|------------------------------------------|
| 99213    | Established office visit | 970 | 0.1 | 100.55, 85.14 | 75.04, 74.70 |
| 99214    | Established patient office or other outpatient, visit typically 25 min | 707 | 0.07 | 144.43, 120.56 | 112.68, 115.18 |
| 36415    | Routine venipuncture | 579 | 0.06 | 8.40, 3.89 | 3.00, 3.00 |
| Q9967    | LOCM 300–399mg/ml iodine, 1ml | 344 | 0.04 | 336.87, 165.17 | 152.19, 165.17 |
| 86617    | Confirmation test for antibody to Borrelia burgdorferi (Lyme disease bacteria) | 308 | 0.03 | 64.58, 32.82 | 28.49, 28.49 |
| 85025    | Complete blood cell count (red cells, leukocyte, platelets), automated test | 287 | 0.03 | 26.57, 18.03 | 14.30, 14.30 |
| 86618    | Analysis for antibody Borrelia burgdorferi (Lyme disease bacteria) | 273 | 0.03 | 42.44, 33.62 | 31.32, 31.32 |
| J3490    | Unclassified drugs | 180 | 0.02 | 489.57, 28.90 | 37.95, 28.90 |
| 97110    | Therapeutic exercises | 166 | 0.02 | 64.88, 49.72 | 33.17, 32.36 |
| J1642    | Injection, heparin sodium, (heparin lock flush), per 10 units | 130 | 0.01 | 248.86, 24.21 | 24.21, 24.21 |
| 80053    | Blood test, comprehensive group of blood chemicals | 105 | 0.01 | 40.06, 14.87 | 19.43, 19.43 |
| 97112    | Neuromuscular reeducation | 102 | 0.01 | 44.74, 25.22 | 34.03, 33.71 |
| 86140    | Measurement C-reactive protein for detection of infection or inflammation | 96 | 0.01 | 21.47, 9.49 | 9.52, 9.52 |
| 83940    | Chiropractic manipulative treatment, 1–2 spinal regions | 88 | 0.01 | 38.20, 28.00 | 29.52, 29.43 |
| 80048    | Blood test, basic group of blood chemicals | 87 | 0.01 | 33.53, 18.90 | 15.55, 15.55 |
| J0696    | Injection, ceftriaxone sodium, per 250 mg | 85 | 0.01 | 165.44, 32.76 | 44.70, 32.76 |
| A9585    | Injection, gadobutrol, 0.1 ml | 83 | 0.01 | 228.98, 90.00 | 90.01, 90.00 |
| 99212    | Established patient office or other outpatient visit, typically 10 min | 82 | 0.01 | 68.39, 51.74 | 45.35, 45.11 |
| 90471    | Administration of 1 vaccine | 78 | 0.01 | 26.87, 24.47 | 26.56, 25.52 |
| 99203    | New patient office or other outpatient visit, typically 30 min | 77 | 0.01 | 138.31, 109.00 | 112.28, 116.07 |
| 85652    | Red blood cell erythrocyte sedimentation rate, to detect inflammation | 76 | 0.01 | 10.53, 4.73 | 4.97, 4.97 |
| 93000    | Routine EKG using at least 12 leads including interpretation and report | 75 | 0.01 | 47.41, 38.79 | 17.95, 18.34 |
| 87880    | Strep test (Streptococcus, group A) | 70 | 0.01 | 20.26, 17.31 | 22.05, 22.05 |
| 99284    | Emergency department visit, problem of high severity | 70 | 0.01 | 532.25, 411.12 | 119.94, 120.87 |
| 85027    | Complete blood cell count (red cells, leukocyte, platelets), automated test | 65 | 0.01 | 23.06, 13.97 | 11.90, 11.90 |
### Appendix Table 7. Societal Perspective: total cost of Lyme disease per participant, by demographic characteristic, n = 613

| Characteristic     | Category                  | N   | Mean (2016 US dollars) | Median (2016 US dollars) |
|--------------------|----------------------------|-----|------------------------|--------------------------|
| Disease category   | Confirmed localized        | 273 | 1307                   | 493                      |
|                    | Confirmed disseminated     | 154 | 3251                   | 1081                     |
|                    | Probable                  | 186 | 2620                   | 940                      |
| Age group, y       | <18                       | 173 | 1550                   | 503                      |
|                    | 18–45                     | 96  | 2100                   | 960                      |
|                    | 46–65                     | 228 | 2421                   | 1136                     |
|                    | >65                       | 116 | 1926                   | 521                      |
| Sex                | Female                    | 262 | 1417                   | 646                      |
|                    | Male                      | 351 | 2497                   | 741                      |
| Race               | Non-White                 | 45  | 2188                   | 774                      |
|                    | White                     | 568 | 2021                   | 685                      |
| State              | CT                        | 128 | 3307                   | 621                      |
|                    | MD                        | 203 | 1493                   | 604                      |
|                    | MN                        | 191 | 2112                   | 1124                     |
| Income*            | <$60,000                  | 160 | 2159                   | 685                      |
|                    | >$60,000                  | 398 | 2088                   | 696                      |
| Insurance          | Private                   | 438 | 2295                   | 807                      |
|                    | Other                     | 175 | 1376                   | 578                      |

*Participants were not required to provide information on income; n = 558.

### Appendix Table 8. Multivariable linear regression results: factors influencing total societal cost of Lyme disease per participant (n = 613)*

| Variable                | Coefficient | Standard error of coefficient | Exp(coefficient) | Percent difference (%) | Cost difference (2016 USD) | 95% CI for cost difference (2016 USD) | P value |
|-------------------------|-------------|-------------------------------|------------------|------------------------|---------------------------|----------------------------------------|---------|
| Baseline (Intercept)*4  | 5.72        | 0.20                          | 305.08           | NA                     | 206.28                   | 206.28 – 451.20                       | <0.001  |
| Confirmed disseminated  | 0.79        | 0.11                          | 2.20             | 120                    | 366.58                   | 188.12 – 545.04                       | <0.001  |
| Probable                | 0.47        | 0.10                          | 1.59             | 59                     | 181.13                   | 70.84 – 291.42                        | <0.001  |
| 18–45 y                 | 0.67        | 0.15                          | 1.96             | 96                     | 292.99                   | 107.11 – 478.88                       | <0.001  |
| 46–65 y                 | 0.73        | 0.11                          | 2.08             | 108                    | 330.79                   | 175.08 – 486.50                       | <0.001  |
| >65 y                   | 0.24        | 0.17                          | 1.27             | 27                     | 83.65                    | –27.51 – 194.81                       | 0.15    |
| Male                    | 0.11        | 0.09                          | 1.11             | 11                     | 34.56                    | –25.67 – 94.8                         | 0.24    |
| MD                      | 0.00        | 0.13                          | 1.00             | 0                      | –0.01                    | –75.98 – 75.97                        | 1.00    |
| MN                      | 0.56        | 0.13                          | 1.75             | 75                     | 229.44                   | 113.85 – 345.03                       | <0.001  |
| NY                      | –0.06       | 0.17                          | 0.94             | –6                     | –18.52                   | –118.96 – 81.91                       | 0.72    |
| Privately insured       | 0.24        | 0.15                          | 1.27             | 27                     | 82.53                    | –23.22 – 188.28                       | 0.11    |
| >$60,000 income         | –0.06       | 0.12                          | 0.94             | –6                     | –18.52                   | –90.11 – 53.08                        | 0.61    |
| Study year 2015         | –0.07       | 0.10                          | 0.93             | –7                     | –21.35                   | 306.05 – 427.11                       | 0.48    |
| Study year 2015         | 0.50        | 0.50                          | 1.65             | 65                     | 197.52                   | –306.37 – 668.64                      | 0.32    |

*The model included independent variables of interest, i.e., disease category, age group, sex, and state, while controlling for insurance status, income, and study year. Reference levels are not shown but are described in Table 6 of main article (https://wwwnc.cdc.gov/EID/article/28/6/21-1335-T5.htm). Adjusted R² = 0.19.
†Beta coefficients were back transformed by exponentiation, interpreted as the multiplicative difference in the geometric mean of the total cost of Lyme disease for a 1-unit difference in the independent variable of interest after adjusting for confounders.
‡Percent difference = (Exp(coefficient) – 1) * 100; this represents the percent change in cost from baseline for each level of each variable, excluding reference (i.e., baseline) levels.
§Baseline cost (i.e., eβ₀) represents a patient with confirmed localized Lyme disease, female, aged <18 y, with residence in CT, without private insurance, with income <$60,000, and study year of 2014.
### Appendix Table 9. Inputs for extrapolation of total Lyme disease cost per participant to aggregate total Lyme disease cost to US society

| Lyme disease category | Estimated proportion of total cases | Total cases | Mean total cost per participant* | Total aggregate cost using mean cost per participant* | Median total cost per participant* | Total aggregate cost using median cost per participant* |
|-----------------------|-------------------------------------|-------------|----------------------------------|------------------------------------------------------|----------------------------------|------------------------------------------------------|
| Confirmed localized    | 0.547                               | 260,435     | 1,307                            | 340,388,077                                         | 493                              | 128,394,278                                         |
| Confirmed disseminated | 0.211                               | 100,278     | 3,251                            | 326,004,293                                         | 1,081                            | 108,400,689                                         |
| Probable              | 0.242                               | 115,287     | 2,620                            | 302,052,464                                         | 940                              | 108,369,968                                         |

*2016 USD

### Appendix Table 10. Estimated annual total Lyme disease cost to US society

| Category | Mean | Median |
|----------|------|--------|
| Total (2016 USD) | 968,444,834 | 345,164,936 |
| Total (2020 USD)* | 1,039,260,297 | 370,404,385 |
| Total (2020 USD, medical CPI)† | 1,078,657,584 | 384,446,034 |

*Converted to 2020 USD using Consumer Price Index, “All items in U.S. city average, all urban consumers, not seasonally adjusted” (CPI-U, Series ID: CUUR0000SA0). 2016 annual average CPI and 2020 first half of year average CPI used. Data extracted from https://data.bls.gov/pdq/SurveyOutputServlet on 9/30/2020.

†Converted to 2020 USD using Consumer Price Index, “Medical care in U.S. city average, all urban consumers, not seasonally adjusted” (CPI-U Medical care, Series ID: CUUR0000SAM). 2016 annual average CPI and 2020 first half of year average CPI used. Data extracted from https://data.bls.gov/pdq/SurveyOutputServlet on 9/30/2020.